Vax-NK/SCLC / Vaxcell-Bio Therap - LARVOL DELTA

VaxCell-Bio partners with ProBio to accelerate CAR-related therapies development (Korea Biomedical Review) - "..the two companies plan to cooperate on the production of phase 1 clinical trial drugs and explore synergies in research (CDO) and manufacturing (CMO) for future next-generation gene therapy pipelines...'Through our partnership with VaxCell-Bio, ProBio will provide customized solutions in high-quality plasmid and viral vector production, CMC development, and GMP manufacturing.'....Leveraging VaxCell-Bio’s deep expertise in NK cell therapy and CAR therapy development, this collaboration is expected to significantly advance their pipeline and introduce innovative therapies to the market, delivering cutting-edge treatments to patients more rapidly, Liu added."

Licensing / partnership • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Small Cell Lung Cancer • Solid Tumor

Vaxcell Bio forms a scientific advisory group and launches an integrated R&D center [Google translation] (HIT News) - "Vaxcell Bio signed a one-year advisory contract with new scientific advisory committee members, including Dr. Byeong-wook Ryu, who has led the research and development of CAR-T treatments in the United States, and Professor Seung-hwan Lee, a professor at the University of Ottawa in Canada, who is considered an authority on immune cell therapy research and development...'With the joining of the two scientists, the research and development of CAR-T, CAR-NK, and CAR-MILs, the Vax-CAR platform built by Vaxcell Bio, will accelerate and will have the effect of being recognized externally.'....Vaxcell Bio believes that the integration of the R&D organization will accelerate the speed of research and development throughout the entire process from basic research to preclinical and clinical trials and increase work efficiency."

Licensing / partnership • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Small Cell Lung Cancer • Solid Tumor

VaxCell-Bio back on track with positive liver cancer clinical progress, capital increase (Korea Biomedical Review) - "As per the Financial Supervisory Service's electronic disclosure system last Sunday, VaxCell-Bio plans to raise about 100 billion won ($75.4 million) through an issuance of 3,938,000 new shares, priced at 25,550 won per share, slated for Sep. 21....In detail, 13.9 billion won will be invested in phase 2b and 3 clinical studies of Vax-NK/HCC, 3.9 billion won in the clinical trial of Vax-NK/PDAC, a pancreatic cancer treatment, and 2.1 billion won in the clinical trial of Vax-NK/SCLC, a small cell lung cancer treatment."

Financing • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor